Curated News
By: NewsRamp Editorial Staff
February 27, 2026
Creative Biotherapeutics Advances CBT300 to Combat Cancer Recurrence and Resistance
TLDR
- Creative Biotherapeutics' CBT300 targets cancer drug resistance and recurrence, offering a potential therapeutic advantage in oncology by addressing mechanisms that cause treatment failure.
- CBT300 is an investigational biologic in preclinical development that interferes with drug-resistance pathways, immune-evasion mechanisms, and processes linked to cancer recurrence and metastasis.
- Inspired by patient loss, CBT300 aims to improve cancer outcomes by developing more effective and tolerable therapies, making tomorrow better for patients and families.
- A biotech company founded by a clinician and biochemist is developing CBT300, a multi-mechanism biologic targeting cancer's ability to resist treatment and return.
Impact - Why it Matters
This news matters because it highlights a promising step forward in addressing some of the most persistent and deadly challenges in cancer treatment: drug resistance, recurrence, and metastasis. For patients and families, these factors often lead to treatment failure and poor outcomes, as seen in the personal story shared by Anita Davidson. By focusing on mechanisms that allow cancers to evade therapies and return, CBT300 could potentially offer new hope for those with aggressive or recurrent cancers, improving survival rates and quality of life. In the broader context, advancements in biologic therapeutics like this contribute to the evolving landscape of precision oncology, moving beyond traditional treatments to target specific biological pathways. This impacts healthcare by potentially reducing the burden of ineffective treatments and offering more tailored, tolerable options, ultimately driving innovation in cancer care and supporting global efforts to combat this disease.
Summary
Creative Biotherapeutics, LLC, a biotechnology company co-founded by healthcare professional Anita Davidson, DPT, and her husband, biochemist Dr. Don Davidson, has announced significant progress in the preclinical development of its investigational biologic therapeutic candidate, CBT300. The company's mission is deeply personal, driven by Anita's recent loss of a sixteen-year-old patient to a recurrent brain cancer, fueling their commitment to addressing the urgent challenges of treatment failure. Led by this experienced duo—Anita with decades in patient recovery and Don with over thirty-five years in drug development and oncology research—the company is advancing CBT300 through rigorous research, validation, and regulatory preparation, with a focus on mechanisms linked to drug resistance, immune evasion, recurrence, and metastasis, aiming to improve outcomes for patients facing aggressive cancers.
The core of Creative Biotherapeutics' work revolves around CBT300, a multi-mechanism biologic candidate designed to interfere with pathways that contribute to cancer's persistence and spread. The company emphasizes a disciplined, evidence-based approach, with development decisions guided by real-world patient experiences and a focus on tolerability, acknowledging the full burden treatments place on patients and families. Currently in the preclinical stage, the program is preparing for FDA-regulated clinical trials, supported by issued and pending patents, and the company is actively seeking mission-aligned collaborations in research, clinical partnerships, and regulatory alignment to accelerate responsible development. For more details, visit their official website to learn about their progress and how to get involved.
Creative Biotherapeutics is publicly sharing information to raise awareness among patients, clinicians, and the scientific community about CBT300 and its development path. The company welcomes collaboration inquiries directed via email, emphasizing a commitment to science-driven oncology solutions that respect patient experiences. With a goal of entering clinical trials soon, the team underscores that progress must be earned through data, discipline, and integrity, as they work toward potentially transformative therapies for cancer. It's important to note that CBT300 remains investigational and has not yet received FDA approval, with forward-looking statements subject to risks and uncertainties.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Creative Biotherapeutics Advances CBT300 to Combat Cancer Recurrence and Resistance
